Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing
Retrieved on:
Monday, September 27, 2021
University of Ferrara, TSOI, Patent, Pharmacy, Clinical trial, Science, Resveratrol, Inflammation, Immunity, Seed, Patient, University of Groningen, Paul Ehrlich Institute, Kidney, Immune system, CEO, University, Company, Nigella sativa, ELK, OTC Markets Group, Yonsei University, COVID-19, SARS, Severe acute respiratory syndrome coronavirus 2, EGCG, Research, Professor of the Russian Academy of Sciences, Degenerative disease, ACE2, Graduate school, Department, Vaccine, Pharmaceutical industry, Animal
On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing's for QuadraMune, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-191.
Key Points:
- On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing's for QuadraMune, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-191.
- Following TSOI's initial research, there have been multiple studies published in peer-reviewed journals by independent academic institutions supporting the individual ingredients in QuadraMune, which are listed below by ingredients.
- To our knowledge, QuadraMune is the only nutraceutical on the market with this level of independent scientific support for its potential use in COVID-19.
- Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.